度普利尤单抗：变应性真菌性鼻-鼻窦炎的一种新兴治疗方法。

Bulkhi Adeeb A, Mirza Ahmad A, Aburiziza Abdullah J, Marglani Osama A

Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.

Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, Fl, USA.

World Allergy Organ J. 2022 Mar 30;15(3):100638. doi: 10.1016/j.waojou.2022.100638. eCollection 2022 Mar.

Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test.

变应性真菌性鼻-鼻窦炎（AFRS）是一种极具抗药性的疾病，治疗颇具挑战性。尽管接受了手术治疗，但仍反复发作该疾病的患者可受益于生物制剂作为辅助治疗。度普利尤单抗在患有慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）的患者中已显示出有前景的治疗终点。本病例系列报告了4例伴有哮喘的难治性AFRS患者，对其给予了度普利尤单抗治疗。长期随访表明，度普利尤单抗改善了症状，并改善了诸如影像学和肺功能测试等客观检查结果。